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Worldwide trends in diabetes since 1980: a pooled analysis of 
751 population-based studies with 4·4 million participants
NCD Risk Factor Collaboration (NCD-RisC)*
Summary
Background One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-
standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how 
likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth 
and ageing, are aﬀ ecting the number of adults with diabetes. 
Methods We pooled data from population-based studies that had collected data on diabetes through measurement of 
its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence—deﬁ ned as fasting 
plasma glucose of 7·0 mmol/L or higher, or history of diagnosis with diabetes, or use of insulin or oral hypoglycaemic 
drugs—in 200 countries and territories in 21 regions, by sex and from 1980 to 2014. We also calculated the posterior 
probability of meeting the global diabetes target if post-2000 trends continue.
Findings We used data from 751 studies including 4 372 000 adults from 146 of the 200 countries we make estimates for. 
Global age-standardised diabetes prevalence increased from 4·3% (95% credible interval 2·4–7·0) in 1980 to 9·0% 
(7·2–11·1) in 2014 in men, and from 5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women. The number of adults with diabetes 
in the world increased from 108 million in 1980 to 422 million in 2014 (28·5% due to the rise in prevalence, 39·7% due 
to population growth and ageing, and 31·8% due to interaction of these two factors). Age-standardised adult diabetes 
prevalence in 2014 was lowest in northwestern Europe, and highest in Polynesia and Micronesia, at nearly 25%, followed 
by Melanesia and the Middle East and north Africa. Between 1980 and 2014 there was little change in age-standardised 
diabetes prevalence in adult women in continental western Europe, although crude prevalence rose because of ageing 
of the population. By contrast, age-standardised adult prevalence rose by 15 percentage points in men and women in 
Polynesia and Micronesia. In 2014, American Samoa had the highest national prevalence of diabetes (>30% in both 
sexes), with age-standardised adult prevalence also higher than 25% in some other islands in Polynesia and Micronesia. 
If post-2000 trends continue, the probability of meeting the global target of halting the rise in the prevalence of diabetes 
by 2025 at the 2010 level worldwide is lower than 1% for men and is 1% for women. Only nine countries for men and 
29 countries for women, mostly in western Europe, have a 50% or higher probability of meeting the global target.
Interpretation Since 1980, age-standardised diabetes prevalence in adults has increased, or at best remained 
unchanged, in every country. Together with population growth and ageing, this rise has led to a near quadrupling of 
the number of adults with diabetes worldwide. The burden of diabetes, both in terms of prevalence and number of 
adults aﬀ ected, has increased faster in low-income and middle-income countries than in high-income countries.
Funding Wellcome Trust.
Copyright © NCD Risk Factor Collaboration. Open Access article distributed under the terms of CC BY.
Introduction
Diabetes is an important cause of mortality, morbidity, 
and health-system costs in the world.1,2 Therefore, there is 
an urgent need to implement population-based inter-
ventions that prevent diabetes, enhance its early detection, 
and use lifestyle and pharmacological interventions to 
prevent or delay its progression to complications. To 
motivate such actions, one of the global targets set after 
the 2011 UN High-Level Meeting on Non-Communicable 
Diseases (NCDs) is to halt, by 2025, the rise in the age-
standardised adult prevalence of diabetes at its 2010 
levels.3 Valid and consistent estimates of diabetes 
prevalence over time are needed to evaluate the eﬀ ect of 
interventions, compare trends in diﬀ erent countries, and 
measure progress towards the agreed target.
A previous study estimated trends in mean fasting 
plasma glucose from 1980 to 2008 and reported diabetes 
prevalence, but only as a secondary outcome and estimated 
based on mean fasting plasma glucose.4 The International 
Diabetes Federation (IDF) periodically reports diabetes 
prevalence,5,6 but does not analyse trends; uses some 
sources that are based solely on self-reported diabetes; and 
does not fully account for diﬀ erences in diabetes 
deﬁ nitions in diﬀ erent data sources,7 even though diabetes 
prevalence varies depending on whether it is deﬁ ned based 
on fasting plasma glucose, 2 h plasma glucose in an oral 
glucose tolerance test (2hOGTT), or haemoglobin A1c 
(HbA1c).8 Furthermore, it is not known how trends in 
prevalence, together with population growth and ageing, 
have aﬀ ected the number of adults with diabetes. Our aim 
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was to estimate worldwide trends in the prevalence and 
number of adults with diabetes. We also estimated the 
probability of achieving the global diabetes target.
Methods
Study design and deﬁ nitions
We estimated trends in diabetes prevalence from 1980 to 
2014, in 200 countries and territories organised into 
21 regions, mostly on the basis of geography and national 
income (appendix pp 11–12). The exception was a region 
consisting of high-income English-speaking countries 
because cardiometabolic risk factors, especially body-mass 
index (BMI), an important risk factor for diabetes, have 
similar trends in these countries, which can be distinct 
from other countries in their geographical region. As the 
primary outcome, diabetes was deﬁ ned as fasting plasma 
glucose of 7·0 mmol/L or higher, history of diagnosis with 
diabetes, or use of insulin or oral hypoglycaemic drugs. 
This deﬁ nition of diabetes is used in the Global Monitoring 
Framework for NCDs;3 it also relies more directly on data 
from population-based health-examination surveys, 
which, for logistical reasons, are more likely to measure 
fasting plasma glucose than 2hOGTT. Our analysis 
covered men and women aged 18 years or older, consistent 
with the Global Monitoring Framework for NCDs.3
Our study had three stages, each described in detail below 
and in the appendix (pp 2–8). First, we identi ﬁ ed, accessed, 
and reanalysed population-based health-examination 
surveys that had measured at least one diabetes biomarker. 
We then converted diabetes prevalence in sources that had 
deﬁ ned diabetes through 2hOGTT or HbA1c or used a cutoﬀ  
other than 7·0 mmol/L for fasting plasma glucose, to a 
corresponding prevalence based on the primary outcome as 
deﬁ ned above. Finally, we applied a statistical model to the 
pooled data to estimate trends for all countries and years.
Data sources
We included data sources that were representative of a 
national, subnational, or community population and that 
had measured at least one of the following diabetes 
biomarkers: fasting plasma glucose, 2hOGTT, and HbA1c. 
We did not use data from sources that relied entirely on 
self-reported history of diagnosis because this approach 
would miss undiagnosed diabetes, which forms a 
substantial share of all people with diabetes, especially in 
communities with little access to health care.9–11 Our 
methods for identifying and accessing data sources are 
described in the appendix (pp 2–6).
History of diabetes diagnosis was established with 
survey-speciﬁ c questions, such as “have you ever been 
told by a doctor or other health professional that you have 
diabetes?” or the combination of “do you now have, or 
have you ever had diabetes?” and “were you told by a 
doctor that you had diabetes?” Similarly, the use of 
diabetes drugs was established with survey-speciﬁ c 
questions, such as “are you currently taking medication 
for diabetes or high blood sugar?” or the combination of 
“do you currently inject insulin for diabetes?” and “are 
you currently taking any medicines, tablets, or pills for 
diabetes?” Some surveys also veriﬁ ed medications with 
use of visual inspection or medical records, or had used 
these approaches to establish the use of diabetes drugs.
Conversion to a consistent deﬁ nition of diabetes
9% of our data were from sources that had reported the 
prevalence of diabetes based on 2hOGTT or HbA1c but not 
Research in context
Evidence before this study
We searched MEDLINE (via PubMed) for articles published 
between Jan 1, 1950, and Dec 11, 2013, with the search terms 
(“Blood Glucose”[MAJR] OR “Diabetes Mellitus”[MAJR:NoExp] 
OR “Diabetes Mellitus, Type 2”[MAJR:NoExp] OR “Diabetes 
Mellitus, Type 1”[MAJR:NoExp] OR “Prediabetic state”[MAJR] 
OR “Hyperglycemia”[MAJR] OR “Hemoglobin A, 
Glycosylated”[MAJR]) AND (“Humans”[Mesh]). Articles were 
screened according to the inclusion and exclusion criteria 
described in the appendix (pp 2–6).
A few studies have reported diabetes trends in one or a few 
countries. A previous study reported diabetes prevalence 
trends to 2008 as a secondary outcome, which was estimated 
from mean fasting plasma glucose. This study was done 
before the global target on diabetes was agreed, hence there 
are no recent data. The International Diabetes Federation 
periodically reports diabetes prevalence but does not analyse 
trends, uses some sources that are only based on self-reported 
diabetes, and does not fully account for diﬀ erences in diabetes 
deﬁ nitions in diﬀ erent data sources.
Added value of this study
This study provides the lengthiest and most complete 
estimates of trends in adult diabetes prevalence worldwide. 
We achieved this level of detail by reanalysing and pooling 
hundreds of population-based sources with actual 
measurements of at least one diabetes biomarker and 
systematically converting all data sources to a common 
deﬁ nition of diabetes. We also systematically projected recent 
trends into the future, and assessed the probability of achieving 
the global diabetes target.
Implications of all the available evidence
Since 1980, age-standardised diabetes prevalence in adults 
increased or at best remained unchanged in every country. 
The burden of diabetes, in terms of both prevalence and 
number of adults aﬀ ected, has increased faster in low-income 
and middle-income countries than in high-income countries. 
If post-2000 trends continue, the probability of meeting the 
global diabetes target is lower than 1% for men and is 1% for 
women worldwide. 
See Online for appendix
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fasting plasma glucose. Another 29% of data were from a 
previous global pooling study4 or extracted from published 
reports and papers, and had used fasting plasma glucose 
but reported only mean plasma con centrations or a 
prevalence based on a cutoﬀ  other than 7·0 mmol/L (eg, 
≥7·8 mmol/L). To correct for in com parability of 
deﬁ nitions of diabetes, we used regressions that converted 
prevalence from these sources to our primary outcome. 
The dependent variable in each of these regressions, 
which are described in detail elsewhere8 and presented in 
the appendix (pp 7–8 and 30–79), was the primary outcome 
(prevalence of fasting plasma glucose ≥7·0 mmol/L or 
history of diabetes diagnosis or use of diabetes drugs), and 
the main independent variable was a prevalence based on 
the deﬁ nitions in at least one study that did not report the 
primary outcome but had some form of data on diabetes 
and glycaemia. The coeﬃ  cients of these regressions were 
estimated from data sources with individual-level data, 
which could be used to calculate prevalence with both 
deﬁ nitions. Details of conversion (or cross-walking) 
regressions, and their speciﬁ cation and coeﬃ  cients, are 
presented in the appendix (pp 30–79). Datapoints based 
on fewer than 25 people were excluded. All regressions 
included terms for age, sex, country, income (natural 
logarithm of per-capita gross domestic product adjusted 
for purchasing power and inﬂ ation), and the year of study. 
When we used more than 400 datapoints to estimate the 
regression coeﬃ  cients, the regressions also included 
regional random eﬀ ects. Finally, we included interaction 
terms in the regressions if the interaction terms provided 
a better ﬁ t to the data as determined by the Bayesian 
Information Criterion.
Statistical analysis
The statistical model used to estimate diabetes prevalence 
by country, year, age, and sex is described in detail in a 
statistical paper and in related substantive papers.12–14 In 
summary, we used a hierarchical probit model in which 
diabetes levels and trends in countries were nested in 
regional levels and trends, which were in turn nested in 
those of super-regions and worldwide. In this structure, 
estimates of diabetes levels and trends for each country 
and year were informed by the country’s own data, if 
available, and by data from other years in the same country 
and in other countries, especially those in the same 
region, with data for similar time periods. The hierarchical 
structure borrows information to a greater degree when 
data are non-existent or weakly informative (eg, because 
they have a small sample size or are not national), and to a 
lesser extent in data-rich countries and regions.
The model incorporated non-linear time trends and 
age patterns, allowing the age pattern of diabetes to vary 
across populations such that the rise in prevalence with 
age would be steeper where diabetes prevalence is 
higher.15 The model accounted for the fact that prevalence 
in subnational and community studies might 
systematically diﬀ er from nationally representative 
surveys, and also tends to have larger variation relative to 
the true values than national studies do. These features 
were implemented by including data-driven ﬁ xed-eﬀ ect 
and random-eﬀ ect terms for subnational and community 
data. The ﬁ xed eﬀ ects adjust for systematic diﬀ erences 
between sub national or community studies and national 
studies. The random eﬀ ects allow national data to have 
larger inﬂ uence on the estimates than subnational or 
community data with similar sample sizes. The model 
also accounted for rural–urban diﬀ erences in diabetes 
prevalence, through the use of data-driven ﬁ xed eﬀ ects 
for rural-only and urban-only studies. These rural and 
urban eﬀ ects were weighted by the diﬀ erence between 
study-level and country-level urbanisation. The statistical 
model also included country-level covariates that help 
predict diabetes prevalence, including average number of 
years of education, proportion of national population 
living in urban areas, a summary measure of availability 
of diﬀ erent food types for human consumption, and age-
standardised adult mean BMI.16 The covariate on food 
availability was constructed from the food balance sheets 
of the Food and Agriculture Organization of the UN, 
with use of principal component analysis. Details of the 
variables, data, and methods are provided elsewhere.13,17
We ﬁ tted this Bayesian model with the Markov chain 
Monte Carlo (MCMC) algorithm. Convergence was 
monitored and 5000 post-burn-in samples were obtained 
from the posterior distribution of model parameters, 
which were then used to obtain the posterior distributions 
of diabetes prevalence. The reported credible intervals 
(CrI) represent the 2·5–97·5 percentiles of the posterior 
distributions.
We report the posterior probability that an estimated 
increase or decrease represents a truly increasing or 
decreasing trend. Posterior probability would be 0·50 in 
a country or region in which an increase is statistically 
indistinguishable from a decrease; a larger posterior 
probability indicates more certainty in a change in 
prevalence. Additionally, we calculated the posterior 
probability of meeting the global target of no increase in 
diabetes prevalence if post-2000 trends continue. All 
analyses were done separately by sex. We used the WHO 
standard population for age standardisation.
We examined how well our model estimates diabetes 
prevalence in countries and years without data by 
withholding some of the data from the model and 
calculating the diﬀ erences between the held-out data 
and the estimates—ie, the error in estimates 
(appendix pp 9–10). This validation test shows that our 
model performed very well; the median errors were close 
to zero globally, and the median absolute errors were 
small (appendix pp 80–84).
Role of funding source
The funder of the study had no role in study design, 
data collection, analysis, interpretation, or writing of 
the report. Country and Regional Data Group 
Articles
1516 www.thelancet.com   Vol 387   April 9, 2016
members, BZ, JB, and MDC had full access to the data 
in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for 
publication.
Results
We used data from 751 population-based measurement 
surveys and studies, which included 4 372 000 participants 
aged 18 years or older. The studies covered 146 (73%) of 
the 200 countries and territories for which estimates 
were made (appendix pp 97–98). These 146 countries 
contained 90% of the world’s adult population in 2014. 
Regionally, the average number of data sources per 
country ranged from less than one in central Africa to 
24 in the high-income Asia Paciﬁ c region. 21 (39%) of the 
54 countries without data were in sub-Saharan Africa, 
11 (20%) in the Caribbean, seven (13%) in central Europe, 
four (7%) in central Asia, and the remaining 11 (20%) in 
other regions. Nearly a third of surveys and studies (242) 
were from years before 2000, and the other two-thirds 
(509) for 2000 and later.
From 1980 to 2014, worldwide age-standardised adult 
diabetes prevalence increased from 4·3% (95% CrI 
2·4–7·0) to 9·0% (7·2–11·1) in men (ﬁ gure 1) and from 
5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women (ﬁ gure 2); 
the posterior probabilities that these were true increases 
were 0·994 and 0·954, respectively. Over these years, 
crude adult prevalence increased from 3·6% (2·0–5·9) to 
8·8% (7·0–10·8) in men, and from 4·7% (2·7–7·4) to 
8·2% (6·6–9·9) in women (ﬁ gures 1, 2).
Age-standardised diabetes prevalence in women in 
2014 was lowest in northwestern and south western 
Europe, which each had a prevalence of less than 5% 
(ﬁ gure 2). The lowest prevalence in adult men was also 
in northwestern Europe, at 5·8% (95% CrI 3·6–8·7). 
Crude adult prevalence in northwestern Europe was 
5·9% (3·8–8·6) for women and 7·9% (5·1–11·5) for 
men in 2014. At the other extreme, age-standardised 
diabetes prevalence was higher than 20% in adult men 
and women in Polynesia and Micronesia, and around 
15% in Melanesia and in the Middle East and 
north Africa.
Over the 35 years of analysis, there was almost no 
change in age-standardised diabetes prevalence in 
women in northwestern and southwestern Europe, 
and only a small non-signiﬁ cant increase in central 
and eastern Europe (ﬁ gure 2). Adult men in 
northwestern Europe also had a smaller rise in 
prevalence than did other regions (ﬁ gure 1). By 
contrast, age-standardised prevalence in Polynesia and 
Micronesia rose by 15·0 (95% CrI 5·5–25·9) percentage 
points in adult men (posterior probability >0·999) and 
by 14·9 (4·5–26·2) percentage points in adult women 
(posterior probability 0·998). Crude adult prevalence 
increased more than age-standardised prevalence in 
regions that had substantial ageing—eg, in high-
income regions.
In 1980, age-standardised adult diabetes prevalence 
was lower than 3% in men in 32 countries and in women 
in 23 countries (ﬁ gures 3, 4). In the same year, age-
standardised prevalence was higher than 12% in adult 
men and women in a few islands in Polynesia and 
Micronesia and women in Kuwait, reaching 25% in men 
and women in Nauru. By 2014, women in only one 
country had an age-standardised adult prevalence lower 
than 3% and women in only nine countries had one 
lower than 4%, with the lowest prevalence estimated in 
some countries in northwestern Europe such as 
Switzerland, Austria, Denmark, Belgium, and the 
Netherlands (ﬁ gure 4). In the same year, age-standardised 
prevalence in adult men was higher than 4% in every 
country (ﬁ gure 3); the lowest estimated prevalences were 
in the same northwestern European countries as those 
for women and in a few countries in east Africa and 
southeast Asia. At the other extreme, age-standardised 
adult diabetes prevalence in 2014 was 31% (95% CrI 
19–44) in men and 33% (21–47) in women in American 
Samoa, and was also higher than 25% in men and 
women in some other islands in Polynesia and 
Micronesia (ﬁ gures 3, 4; appendix pp 85–94).
No country had a statistically signiﬁ cant decrease in 
diabetes prevalence from 1980 to 2014 (ﬁ gure 5), although 
the relative increase over these 35 years was lower than 
20% in nine countries for men, mostly in northwestern 
Europe, and in 39 countries for women. Over the same 
period, age-standardised adult prevalence of diabetes at 
least doubled for men in 120 countries and for women in 
87 countries, with a posterior probability of 0·887 or 
higher. The largest absolute increases in age-standardised 
adult prevalence were in Oceania, exceeding 
15 percentage points in some countries, followed by the 
Middle East and north Africa (ﬁ gure 5).
Worldwide, if post-2000 trends continue, the 
probability of meeting the global diabetes target for 
men is lower than 1%; for women it is 1%. Only nine 
countries, mostly in northwestern Europe, had a 50% 
or higher probability of meeting the global target for 
men, as did 29 countries for women (ﬁ gure 6). Rather, 
if post-2000 trends continue, age-standardised 
prevalence of diabetes in 2025 will be 12·8% (95% CrI 
8·3–19·6) in men and 10·4% (7·1–15·1) in women. The 
number of adults with diabetes will surpass 700 million.
The number of adults with diabetes in the world 
increased from 108 million in 1980, to 422 million in 2014 
(ﬁ gure 7). East Asia and south Asia had the largest rises of 
absolute numbers, and had the largest number of people 
with diabetes in 2014: 106 million and 86 million, 
respectively. 39·7% (n=124·8 million) of the rise in the 
number of people with diabetes was due to population 
growth and ageing, 28·5% (n=89·7 million) due to the 
rise in age-speciﬁ c prevalences, and the remaining 31·8% 
(n=99·9 million) due to the interaction of the two—ie, an 
older and larger population with higher age-speciﬁ c 
prevalences (ﬁ gure 7).
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Figure 1: Trends in age-standardised and crude prevalence of diabetes for men by region
The lines (solid for age-standardised and dashed for crude) show the posterior mean estimates; the shaded area shows the 95% credible intervals for age-standardised prevalence. For trends and numerical 
results by country see appendix pp 85–94, 103–170.
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Figure 2: Trends in age-standardised and crude prevalence of diabetes for women by region
The lines (solid for age-standardised and dashed for crude) show the posterior mean estimates; the shaded area shows the 95% credible intervals for age-standardised prevalence. For trends and numerical 
results by country see appendix pp 85–94, 103–170.
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Figure 3 : Age-standardised prevalence of diabetes in adult men by country in 1980 and 2014
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Figure 4: Age-standardised prevalence of diabetes in adult women by country in 1980 and 2014
Articles
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Half of adults with diabetes in 2014 lived in ﬁ ve 
countries: China, India, the USA, Brazil, and Indonesia 
(ﬁ gure 8). These countries also accounted for one half of 
the world’s adult population in 2014. Although the top 
three countries on this list remained unchanged from 
1980 to 2014, the global share of adults with diabetes who 
live in China and India increased, by contrast with the 
USA, where the share decreased. The changes in the 
share of adults with diabetes from India and the USA 
might be partly because of the changes in their shares. 
However, the share of the adult population of China 
remained virtually unchanged, while its share of the 
adult population with diabetes increased. Low-income 
and middle-income countries, including Indonesia, 
Pakistan, Mexico, and Egypt, replaced European 
countries, including Germany, Ukraine, Italy, and the 
UK, on the list of the top ten countries with most adults 
with diabetes (ﬁ gure 8).
Discussion
We used population-based data to document the global 
diabetes epidemic since 1980. Over this period, 
age-standardised diabetes prevalence in adults increased 
or at best remained unchanged in every country. It more 
than doubled in men and increased by 60% in women 
worldwide, shifting from an excess prevalence in women 
in 1980, to a higher male prevalence in 2014.18,19 This rise 
in prevalence has been compounded by population 
growth and ageing, nearly quadrupling the number 
of adults with diabetes over these 35 years. The burden of 
diabetes, both in terms of prevalence and number of 
adults with diabetes, increased at a greater rate 
in low-income and middle-income countries than 
in high-income countries. The highest national 
prevalences—generally those in Oceania, and the Middle 
East and north Africa—are now ﬁ ve to ten times greater 
than the lowest prevalences, which are in some western 
European countries.
Our estimates of diabetes prevalence for 2013 for the 
world as a whole are similar to those by the IDF for the 
same year,5,6 but there were diﬀ erences between our 
estimates and those from the IDF in some countries and 
regions. In particular, we estimated a higher age-
standardised prevalence of diabetes in most countries in 
the Middle East and north Africa than the IDF. The IDF 
does not estimate trends, hence we could not compare 
trend estimates. Our ﬁ nding that diabetes prevalence 
was low in much of Asia and sub-Saharan Africa in the 
1980s and 1990s is consistent with other studies that 
found low prevalences in these regions in those 
decades.20,21 Our ﬁ nding that diabetes prevalence did not 
increase in continental western Europe (especially in 
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Figure 6: Probability of achieving the target of halting the rise of diabetes in adults by 2025 at its 2010 levels by sex and country if post-2000 trends continue
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northwestern Europe) is also consistent with reports 
from Sweden,22 Germany,23 and Switzerland24 that covered 
a subset of our analysis years. Similarly, our estimated 
increases for high-income English-speaking countries 
are consistent with studies that had analysed repeated 
population-based surveys in the USA25 and the UK.26,27 A 
meta-analysis of 15 studies in Japan reported no increase 
in diabetes prevalence,28 as observed in our analysis. 
Several recent reports have also documented similar 
increases in diabetes prevalence to those observed in our 
analysis in China,29,30 India,31–34 Iran,35 Turkey,36 and Saudi 
Arabia.37 Finally, our ﬁ nding of the slower rise in diabetes 
prevalence in women compared with men is consistent 
with historical data in a few high-income countries.18,19
The larger rise in diabetes prevalence in low-income and 
middle-income countries than in high-income countries, 
and the mostly ﬂ at trends in Europe (especially in 
northwestern Europe), might be caused by several factors. 
First, adiposity, which is an important risk factor for 
diabetes, has increased substantially more, and is now 
higher, in many low-income and middle-income countries 
than in continental Europe and high-income Asia Paciﬁ c 
countries, especially in women.16 Second, regional 
diﬀ erences in diabetes could be due in part to diﬀ erences 
in genetic susceptibility or phenotypic variations arising 
from inadequate fetal and childhood nutrition and growth; 
earlier onset of β-cell dysfunction might be one 
diﬀ erentiating characteristic of Asian populations 
compared with European populations.38–42 Third, better-
resourced health systems in Europe and other high-
income countries might identify people at high risk of 
diabetes at an earlier stage, and use lifestyle and dietary 
modiﬁ cation or drugs to prevent or delay its onset.43–45 At 
the moment, information on the proportion of people 
with, or at risk of, diabetes who are diagnosed and receive 
treatment is limited to a few countries. Consistent 
information on diagnosis and treatment coverage will 
become increasingly important as universal health 
coverage becomes a central theme of global health eﬀ orts, 
and should be a focus of future analyses. Finally, in 
addition to total caloric intake and adiposity, dietary 
composition and physical activity might aﬀ ect diabetes risk 
and contribute to diﬀ erences in regional trends.46 These 
and other potential reasons for the divergent trends in 
diabetes prevalence should be investigated. Furthermore, 
the shift in diabetes burden from women towards men 
might be due to men having higher prevalences of some 
risk factors for diabetes, such as smoking, or being at risk 
of diabetes at lower BMI levels than are women.18,19
The strengths of our study include its scope of making 
consistent and comparable estimates of trends in diabetes 
prevalence and of the probabilities of meeting the global 
diabetes target. We used an unprecedented amount of 
population-based data, which came from countries in 
which 90% of the global adult population lives. We used 
only data from studies that had measured a diabetes 
biomarker to avoid bias in self-reported data. Data were 
analysed according to a common protocol, and the 
characteristics and quality of data sources were rigorously 
veriﬁ ed through repeated checks by Collaborating Group 
members from each country. We pooled data using a 
statistical model that took into account the epidemiological 
features of diabetes, including non-linear time trends and 
age associations, and used all available data while giving 
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more weight to national data than to subnational and 
community sources.
Despite our extensive eﬀ orts to identify and access 
worldwide population-based data, some countries had no 
or few data sources, especially those in sub-Saharan 
Africa, the Caribbean, central Asia, and central Europe. 
Estimates for these countries relied mostly or entirely on 
the statistical model, which shares information across 
countries and regions through its hierarchy and through 
predictive covariates. The absence or scarcity of data is 
reﬂ ected in wider uncertainty intervals of our estimates 
for these countries and regions (ﬁ gures 1, 2; appendix 
pp 103–170). Diabetes was reported using a deﬁ nition 
other than our primary outcome in some data sources, 
either because fasting plasma glucose was not measured 
or because individual-level data could not be accessed. To 
overcome this issue, we systematically used the reported 
metrics to estimate our primary outcome; the cross-
walking regressions used for this purpose had good 
predictive accuracy. The share of studies that used a 
portable device (instead of laboratory analysis) for 
measuring diabetes biomarkers has increased over time. 
We do not expect the rise in the use of portable devices to 
aﬀ ect the estimated levels and trends because their 
higher use in population-based research is partly due to 
increasing similarity between their measurements and 
those in laboratory-based tests,47,48 facilitated by more 
advanced technologies and better standardisation. 
Further, although our primary outcome is consistent 
with the NCD Global Monitoring Framework, diabetes 
prevalence based on fasting plasma glucose alone is 
lower than that based on the combination of fasting 
plasma glucose and 2hOGTT.8 Age-standardised adult 
diabetes prevalence would be 10·0% (95% CrI 8·0–12·5) 
for men and 8·8% (7·2–10·7) for women, worldwide, if 
we applied the cross-walking regression (similar to those 
in appendix pp 34–79) to convert our estimates to 
prevalence of diabetes deﬁ ned as fasting plasma glucose 
of 7·0 mmol/L or higher, or 2hOGTT of 11·1 mmol/L or 
higher, or history of diagnosis with diabetes or use of 
insulin or oral hypoglycaemic drugs. Finally, the survey 
data did not separate type 1 and type 2 diabetes because 
distinguishing between these disorders is diﬃ  cult in 
adults.49–51 However, most (85–95%) cases of diabetes in 
adults are type 2,50,52 so the observed rise in diabetes 
prevalence in adults is quite likely due to increases in 
type 2 diabetes. 
Diabetes and its macrovascular and microvascular 
complications account for more than 2 million deaths 
every year,1 and are the seventh leading cause of disability 
worldwide.53 Diabetes is also a risk factor for tuberculosis, 
another disease with large burden in low-income and 
middle-income countries.54 Diabetes and its compli-
cations impose substantial economic costs on patients, 
their families, health systems, and national economies 
because of direct costs of treatment and loss of work and 
wages.2 On the basis of estimates for the number of 
people with diabetes in 2014 in this study, and cost 
estimates from a systematic review,2 the direct annual 
cost of diabetes in the world is Intl$825 billion, with 
China ($170 billion), the USA ($105 billion), India 
($73 billion), and Japan ($37 billion) having the largest 
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Figure 8: Ten countries with the largest number of adults with diabetes in 1980 and 2014
Colours for each country indicate its region.
Articles
www.thelancet.com   Vol 387   April 9, 2016 1525
Mohammed K Ali (Emory University, USA); Cristina Taddei (University 
of Florence, Italy); Wei-Cheng Lo (National Taiwan University, Taiwan); 
Barbara Reis-Santos (Universidade Federal de Pelotas, Brazil); 
Gretchen A Stevens (World Health Organization, Switzerland); 
Leanne M Riley (World Health Organization, Switzerland); 
J Jaime Miranda (Universidad Peruana Cayetano Heredia, Peru); 
Prof Peter Bjerregaard (University of Southern Denmark, Denmark; 
University of Greenland, Greenland); Prof Juan A Rivera (Instituto 
Nacional de Salud Pública, Mexico); Heba M Fouad (World Health 
Organization Regional Oﬃ  ce for the Eastern Mediterranean, Egypt); 
Prof Guansheng Ma (Peking University, China); 
Prof Jean Claude N Mbanya (University of Yaoundé 1, Cameroon); 
Prof Stephen T McGarvey (Brown University, USA); 
Viswanathan Mohan (Madras Diabetes Research Foundation, India); 
Prof Altan Onat (Istanbul University, Turkey); Aida Pilav (Federal 
Ministry of Health, Bosnia and Herzegovina); 
Prof Ambady Ramachandran (India Diabetes Research Foundation, 
India); Prof Habiba Ben Romdhane (University Tunis El Manar, 
Tunisia); Christopher J Paciorek (University of California, Berkeley, 
USA); James E Bennett (Imperial College London, UK); 
Prof Majid Ezzati (Imperial College London, UK).
Country and Regional Data (*equal contribution; listed alphabetically)—
Ziad A Abdeen (Al-Quds University, Palestine)*; Khalid Abdul Kadir 
(Monash University Malaysia, Malaysia)*; Niveen M Abu-Rmeileh 
(Birzeit University, Palestine)*; Benjamin Acosta-Cazares (Instituto 
Mexicano del Seguro Social, Mexico)*; Robert Adams (The University of 
Adelaide, Australia)*; Wichai Aekplakorn (Mahidol University, 
Thailand)*; Carlos A Aguilar-Salinas (Instituto Nacional de Ciencias 
Médicas y Nutricion, Mexico)*; Charles Agyemang (University of 
Amsterdam, Netherlands)*; Alireza Ahmadvand (Non-Communicable 
Diseases Research Center, Iran)*; Amani Rashed Al-Othman (Kuwait 
Institute for Scientiﬁ c Research, Kuwait)*; Ala’a Alkerwi (Luxembourg 
Institute of Health, Luxembourg)*; Philippe Amouyel (Lille University 
and Hospital, France)*; Antoinette Amuzu (London School of Hygiene 
& Tropical Medicine, UK)*; Lars Bo Andersen (University of Southern 
Denmark, Denmark)*; Sigmund A Anderssen (Norwegian School of 
Sport Sciences, Norway)*; Ranjit Mohan Anjana (Madras Diabetes 
Research Foundation, India)*; Hajer Aounallah-Skhiri (National 
Institute of Public Health, Tunisia)*; Tahir Aris (Ministry of Health 
Malaysia, Malaysia)*; Nimmathota Arlappa (Indian Council of Medical 
Research, India)*; Dominique Arveiler (Strasbourg University and 
Hospital, France)*; Felix K Assah (University of Yaoundé 1, Cameroon)*; 
Mária Avdicová (Regional Authority of Public Health, Banska Bystrica, 
Slovakia)*; Fereidoun Azizi (Shahid Beheshti University of Medical 
Sciences, Iran)*; Nagalla Balakrishna (Indian Council of Medical 
Research, India)*; Piotr Bandosz (Medical University of Gdansk, 
Poland)*; Carlo M Barbagallo (University of Palermo, Italy)*; 
Alberto Barceló (Pan American Health Organization, USA)*; 
Anwar M Batieha (Jordan University of Science and Technology, 
Jordan)*; Louise A Baur (University of Sydney, Australia)*; 
Habiba Ben Romdhane (University Tunis El Manar, Tunisia)*; 
Mikhail Benet (University Medical Science, Cuba)*; 
Antonio Bernabe-Ortiz (Universidad Peruana Cayetano Heredia, Peru)*; 
Sumit Bharadwaj (Chirayu Medical College, India)*; Santosh K Bhargava 
(Sunder Lal Jain Hospital, India)*; Yufang Bi (Shanghai Jiao-Tong 
University School of Medicine, China)*; Peter Bjerregaard (University of 
Southern Denmark, Denmark; University of Greenland, Greenland)*; 
Espen Bjertness (University of Oslo, Norway)*; Marius B Bjertness 
(University of Oslo, Norway)*; Cecilia Björkelund (University of 
Gothenburg, Sweden)*; Anneke Blokstra (National Institute for Public 
Health and the Environment, Netherlands)*; Simona Bo (University of 
Turin, Italy)*; Bernhard O Boehm (Nanyang Technological University, 
Singapore)*; Carlos P Boissonnet (Centro de Educación Médica e 
Investigaciones Clínicas, Argentina)*; Pascal Bovet (Ministry of Health, 
Seychelles; University of Lausanne, Switzerland)*; Imperia Brajkovich 
(Universidad Central de Venezuela, Venezuela)*; Juergen Breckenkamp 
(Bielefeld University, Germany)*; Hermann Brenner (German Cancer 
Research Center, Germany)*; Lizzy M Brewster (University of 
Amsterdam, Netherlands)*; Garry R Brian (The Fred Hollows 
Foundation New Zealand, New Zealand)*; Graziella Bruno (University 
of Turin, Italy)*; Anna Bugge (University of Southern Denmark, 
costs. Nearly 60% of the global costs are borne by low-
income and middle-income countries, where substantial 
parts of treatment costs are paid out-of-pocket,2 which 
aﬀ ects treatment utilisation and adherence and leads to 
ﬁ nancial hardship for patients and their families.
Glucose reduction with lifestyle modiﬁ cation and 
drugs in people with diabetes, especially if started early, 
can delay progression to microvascular complications.55–57 
Although evidence is mixed from trials on the 
macrovascular beneﬁ ts of intensive glucose lowering,55,58–60 
long-term glycaemic control and lowering blood pressure 
and serum cholesterol also reduce the risk of adverse 
cardiovascular outcomes.61,62 However, the eﬀ ectiveness 
of these interventions at the population level has been 
slight, both because many diabetes cases remain 
undiagnosed9–11 and because adherence to treatment is 
typically lower in general populations than in those 
enrolled in clinical trials.63–65
Eﬀ orts to reduce the global health and economic 
burden of diabetes should emphasise prevention of 
diabetes or delaying its onset, through enhancing healthy 
behaviours and diets at the population level, and early 
detection and management of high-risk individuals. 
There has been little success in preventing obesity,16 the 
most important risk factor for diabetes, at the population 
level although the global target on obesity could engender 
new eﬀ orts and policy innovations. As these policies are 
implemented, identifying people at high risk of 
diabetes—especially those with impaired glucose 
tolerance—through the primary care system, using 
advice and support to induce and maintain lifestyle 
change, possibly together with drugs such as metformin, 
might be the only short-term approach for global diabetes 
prevention.44,64,66,67 Such programmes have been imple-
mented in a few high-income and middle-income 
countries,45,68,69 but their success elsewhere requires a 
ﬁ nancially accessible primary care system that prioritises 
diabetes prevention and management and is staﬀ ed and 
resourced to support lifestyle change and improve access 
to and adherence to medication.10,43,45,64,68,70
Contributors
ME and GD designed the study and oversaw research. Members of the 
Country and Regional Data Group collected and reanalysed data, and 
checked pooled data for accuracy of information about their study and other 
studies in their country. BZ, YL, KH, and MDC led data collection. BZ, JB, 
and YL led the statistical analysis and prepared results. Members of the 
Pooled Analysis and Writing Group collated data, checked all data sources in 
consultation with the Country and Regional Data Group, analysed pooled 
data, and prepared results. ME wrote the ﬁ rst draft of the report with input 
from other members of Pooled Analysis and Writing Group. Members of 
Country and Regional Data Group commented on the draft report.
NCD Risk Factor Collaboration
Pooled Analysis and Writing (*equal contribution)—Bin Zhou (Imperial 
College London, UK)*; Yuan Lu (Harvard T H Chan School of Public 
Health, USA)*; Kaveh Hajifathalian (Harvard T H Chan School of Public 
Health, USA)*; James Bentham (Imperial College London, UK)*; 
Mariachiara Di Cesare (Imperial College London, UK; Middlesex 
University, UK)*; Goodarz Danaei (Harvard T H Chan School of Public 
Health, USA)*; Honor Bixby (Imperial College London, UK); 
Melanie J Cowan (World Health Organization, Switzerland); 
Articles
1526 www.thelancet.com   Vol 387   April 9, 2016
Denmark)*; Antonio Cabrera de León (University La Laguna, Spain)*; 
Günay Can (Istanbul University, Turkey)*; Ana Paula C Cândido 
(Universidade Federal de Juiz de Fora, Brazil)*; Vincenzo Capuano 
(Cardiologia di Mercato S Severino, Italy)*; Axel C Carlsson (Karolinska 
Institutet, Sweden)*; Maria J Carvalho (University of Porto, Portugal)*; 
Felipe F Casanueva (Santiago de Compostela University, Spain)*; 
Juan-Pablo Casas (University College London, UK)*; Carmelo A Caserta 
(Associazione Calabrese di Epatologia, Italy)*; Katia Castetbon (French 
Institute for Health Surveillance, France)*; Snehalatha Chamukuttan 
(India Diabetes Research Foundation, India)*; Nishi Chaturvedi 
(University College London, UK)*; Chien-Jen Chen (Academia Sinica, 
Taiwan)*; Fangfang Chen (Capital Institute of Pediatrics, China)*; 
Shuohua Chen (Kailuan General Hospital, China)*; Ching-Yu Cheng 
(Duke-NUS Graduate Medical School, Singapore)*; Angela Chetrit (The 
Gertner Institute for Epidemiology and Health Policy Research, Israel)*; 
Shu-Ti Chiou (Ministry of Health and Welfare, Taiwan)*; Yumi Cho 
(Korea Centers for Disease Control and Prevention, Republic of Korea)*; 
Jerzy Chudek (Medical University of Silesia, Poland)*; Renata Cifkova 
(Charles University in Prague, Czech Republic)*; Frank Claessens 
(Katholieke Universiteit Leuven, Belgium)*; Hans Concin (Agency for 
Preventive and Social Medicine, Austria)*; Cyrus Cooper (University of 
Southampton, UK)*; Rachel Cooper (University College London, UK)*; 
Simona Costanzo (IRCCS Istituto Neurologico Mediterraneo Neuromed, 
Italy)*; Dominique Cottel (Institut Pasteur de Lille, France)*; 
Chris Cowell (Westmead University of Sydney, Australia)*; 
Ana B Crujeiras (CIBEROBN, Spain)*; Graziella D’Arrigo (National 
Council of Research, Italy)*; Jean Dallongeville (Institut Pasteur de Lille, 
France)*; Rachel Dankner (The Gertner Institute for Epidemiology and 
Health Policy Research, Israel)*; Luc Dauchet (Lille University Hospital, 
France)*; Giovanni de Gaetano (IRCCS Istituto Neurologico 
Mediterraneo Neuromed, Italy)*; Stefaan De Henauw (Ghent University, 
Belgium)*; Mohan Deepa (Madras Diabetes Research Foundation, 
India)*; Abbas Dehghan (Erasmus Medical Center Rotterdam, 
Netherlands)*; Valerie Deschamps (French Institute for Health 
Surveillance, France)*; Klodian Dhana (Erasmus Medical Center 
Rotterdam, Netherlands)*; Augusto F Di Castelnuovo (IRCCS Istituto 
Neurologico Mediterraneo Neuromed, Italy)*; Shirin Djalalinia (Non-
Communicable Diseases Research Center, Iran)*; Kouamelan Doua 
(Ministère de la Santé et de la Lutte Contre le Sida, Côte d’Ivoire)*; 
Wojciech Drygas (The Cardinal Wyszynski Institute of Cardiology, 
Poland)*; Yong Du (Robert Koch Institute, Germany)*; Vilnis Dzerve 
(University of Latvia, Latvia)*; Eruke E Egbagbe (University of Benin, 
Nigeria)*; Robert Eggertsen (University of Gothenburg, Sweden)*; 
Jalila El Ati (National Institute of Nutrition and Food Technology, 
Tunisia)*; Roberto Elosua (Institut Hospital del Mar d’Investigacions 
Mèdiques, Spain)*; Rajiv T Erasmus (University of Stellenbosch, South 
Africa)*; Cihangir Erem (Karadeniz Technical University, Turkey)*; 
Gul Ergor (Dokuz Eylul University, Turkey)*; Louise Eriksen (University 
of Southern Denmark, Denmark)*; Jorge Escobedo-de la Peña (Instituto 
Mexicano del Seguro Social, Mexico)*; Caroline H Fall (University of 
Southampton, UK)*; Farshad Farzadfar (Tehran University of Medical 
Sciences, Iran)*; Francisco J Felix-Redondo (Centro de Salud Villanueva 
Norte, Spain)*; Trevor S Ferguson (The University of the West Indies, 
Jamaica)*; Daniel Fernández-Bergés (Hospital Don Benito-Villanueva de 
la Serena, Spain)*; Marika Ferrari (Council for Agricultural Research 
and Economics, Italy)*; Catterina Ferreccio (Pontiﬁ cia Universidad 
Católica de Chile, Chile)*; Edith JM Feskens (Wageningen University, 
The Netherlands)*; Joseph D Finn (University of Manchester, UK)*; 
Bernhard Föger (Agency for Preventive and Social Medicine, Austria)*; 
Leng Huat Foo (Universiti Sains Malaysia, Malaysia)*; 
Ann-Soﬁ e Forslund (Luleå University, Sweden)*; Heba M Fouad (World 
Health Organization Regional Oﬃ  ce for the Eastern Mediterranean, 
Egypt)*; Damian K Francis (The University of the West Indies, 
Jamaica)*; Maria do Carmo Franco (Federal University of São Paulo, 
Brazil)*; Oscar H Franco (Erasmus Medical Center Rotterdam, 
Netherlands)*; Guillermo Frontera (Hospital Universitario Son Espases, 
Spain)*; Takuro Furusawa (Kyoto University, Japan)*; Zbigniew Gaciong 
(Medical University of Warsaw, Poland)*; Sarah P Garnett (University of 
Sydney, Australia)*; Jean-Michel Gaspoz (Geneva University Hospitals, 
Switzerland)*; Magda Gasull (CIBER en Epidemiología y Salud Pública, 
Spain)*; Louise Gates (Australian Bureau of Statistics, Australia)*; 
Johanna M Geleijnse (Wageningen University, Netherlands)*; 
Anoosheh Ghasemian (Non-Communicable Diseases Research Center, 
Iran)*; Anup Ghimire (B P Koirala Institute of Health Sciences, Nepal)*; 
Simona Giampaoli (Istituto Superiore di Sanità, Italy)*; 
Francesco Gianfagna (University of Insubria, Italy)*; 
Jonathan Giovannelli (Lille University Hospital, France)*; 
Aleksander Giwercman (Lund University, Sweden)*; 
Marcela Gonzalez Gross (Universidad Politécnica de Madrid, Spain)*; 
Juan P González Rivas (The Andes Clinic of Cardio-Metabolic Studies, 
Venezuela)*; Mariano Bonet Gorbea (National Institute of Hygiene, 
Epidemiology and Microbiology, Cuba)*; Frederic Gottrand (Université 
de Lille 2, France)*; Dušan Grafnetter (Institute for Clinical and 
Experimental Medicine, Czech Republic)*; Tomasz Grodzicki 
(Jagiellonian University Medical College, Poland)*; Anders Grøntved 
(University of Southern Denmark, Denmark)*; Grabriella Gruden 
(University of Turin, Italy)*; Dongfeng Gu (National Center of 
Cardiovascular Diseases, China)*; Ong Peng Guan (Singapore Eye 
Research Institute, Singapore)*; Ramiro Guerrero (Universidad Icesi, 
Colombia)*; Idris Guessous (Geneva University Hospitals, 
Switzerland)*; Andre L Guimaraes (State University of Montes Claros, 
Brazil)*; Laura Gutierrez (Institute for Clinical Eﬀ ectiveness and Health 
Policy, Argentina)*; Ian R Hambleton (The University of the West 
Indies, Barbados)*; Rebecca Hardy (University College London, UK)*; 
Rachakulla Hari Kumar (Indian Council of Medical Research, India)*; 
Jun Hata (Kyushu University, Japan)*; Jiang He (Tulane University, 
USA)*; Christin Heidemann (Robert Koch Institute, Germany)*; 
Sauli Herrala (Oulu University Hospital, Finland)*; 
Ilpo Tapani Hihtaniemi (Imperial College London, UK)*; Sai Yin Ho 
(University of Hong Kong, China)*; Suzanne C Ho (The Chinese 
University of Hong Kong, China)*; Albert Hofman (Erasmus Medical 
Center Rotterdam, Netherlands)*; Claudia M Hormiga (Fundación 
Oftalmológica de Santander, Colombia)*; Bernardo L Horta 
(Universidade Federal de Pelotas, Brazil)*; Leila Houti (University of 
Oran 1, Algeria)*; Christina Howitt (The University of the West Indies, 
Barbados)*; Thein Thein Htay (Ministry of Health, Myanmar)*; 
Aung Soe Htet (University of Oslo, Norway)*; 
Maung Maung Than Htike (Ministry of Health, Myanmar)*; Yang Hu 
(Harvard T H Chan School of Public Health, USA)*; 
Abdullatif S Hussieni (Birzeit University, Palestine)*; Inge Huybrechts 
(International Agency for Research on Cancer, France)*; Nahla Hwalla 
(American University of Beirut, Lebanon)*; Licia Iacoviello (IRCCS 
Istituto Neurologico Mediterraneo Neuromed, Italy)*; Anna G Iannone 
(Cardiologia di Mercato S. Severino, Italy)*; M Mohsen Ibrahim (Cairo 
University, Egypt)*; Nayu Ikeda (National Institute of Health and 
Nutrition, Japan)*; M Arfan Ikram (Erasmus Medical Center Rotterdam, 
Netherlands)*; Vilma E Irazola (Institute for Clinical Eﬀ ectiveness and 
Health Policy, Argentina)*; Muhammad Islam (Aga Khan University, 
Pakistan)*; Masanori Iwasaki (Niigata University, Japan)*; 
Jeremy M Jacobs (Hadassah University Medical Center, Israel)*; 
Tazeen Jafar (Duke-NUS Graduate Medical School, Singapore)*; 
Kazi M Jamil (Kuwait Institute for Scientiﬁ c Research, Kuwait)*; 
Grazyna Jasienska (Jagiellonian University Medical College, Poland)*; 
Chao Qiang Jiang (University of Hong Kong, China)*; Jost B Jonas 
(Ruprecht-Karls-University of Heidelberg, Germany)*; Pradeep Joshi 
(World Health Organization Country Oﬃ  ce, India)*; Anthony Kafatos 
(University of Crete, Greece)*; Ofra Kalter-Leibovici (The Gertner 
Institute for Epidemiology and Health Policy Research, Israel)*; 
Amir Kasaeian (Non-Communicable Diseases Research Center, Iran)*; 
Joanne Katz (Johns Hopkins Bloomberg School of Public Health, USA)*; 
Prabhdeep Kaur (National Institute of Epidemiology, India)*; 
Maryam Kavousi (Erasmus Medical Center Rotterdam, Netherlands)*; 
Sirkka Keinänen-Kiukaanniemi (Oulu University Hospital, Finland)*; 
Roya Kelishadi (Research Institute for Primordial Prevention of Non-
Communicable Disease, Iran)*; Andre P Kengne (South African Medical 
Research Council, South Africa)*; Mathilde Kersting (Research Institute 
of Child Nutrition, Germany)*; Yousef Saleh Khader (Jordan University 
of Science and Technology, Jordan)*; Davood Khalili (Shahid Beheshti 
University of Medical Sciences, Iran)*; Young-Ho Khang (Seoul National 
University, Republic of Korea)*; Stefan Kiechl (Medical University 
Innsbruck, Austria)*; Jeongseon Kim (National Cancer Center, Republic 
of Korea)*; Patrick Kolsteren (Institute of Tropical Medicine, Belgium)*; 
Articles
www.thelancet.com   Vol 387   April 9, 2016 1527
Paul Korrovits (Tartu University Clinics, Estonia)*; Wolfgang Kratzer 
(University Hospital Ulm, Germany)*; Daan Kromhout (Wageningen 
University, Netherlands)*; Urho M Kujala (University of Jyväskylä, 
Finland)*; Krzysztof Kula (Medical University of Łodz, Poland)*; 
Catherine Kyobutungi (African Population and Health Research Center, 
Kenya)*; Tiina Laatikainen (National Institute for Health and Welfare, 
Finland)*; Carl Lachat (Ghent University, Belgium)*; Youcef Laid (INSP, 
Algeria)*; Tai Hing Lam (University of Hong Kong, China)*; 
Orlando Landrove (Ministerio de Salud Pública, Cuba)*; Vera Lanska 
(Institute for Clinical and Experimental Medicine, Czech Republic)*; 
Georg Lappas (Sahlgrenska Academy, Sweden)*; Avula Laxmaiah 
(Indian Council of Medical Research, India)*; Catherine Leclercq (Food 
and Agriculture Organization, Italy)*; Jeannette Lee (National University 
of Singapore, Singapore)*; Jeonghee Lee (National Cancer Center, 
Republic of Korea)*; Terho Lehtimäki (Tampere University Hospital, 
Finland)*; Rampal Lekhraj (Universiti Putra Malaysia, Malaysia)*; 
Luz M León-Muñoz (Universidad Autónoma de Madrid, Spain)*; 
Yanping Li (Harvard T H Chan School of Public Health, USA)*; 
Wei-Yen Lim (National University of Singapore, Singapore)*; 
M Fernanda Lima-Costa (Oswaldo Cruz Foundation Rene Rachou 
Research Institute, Brazil)*; Hsien-Ho Lin (National Taiwan University, 
Taiwan)*; Xu Lin (University of Chinese Academy of Sciences, China)*; 
Lauren Lissner (University of Gothenburg, Sweden)*; Roberto Lorbeer 
(University Medicine Greifswald, Germany)*; José Eugenio Lozano 
(Consejería de Sanidad Junta de Castilla y León, Spain)*; Dalia Luksiene 
(Lithuanian University of Health Sciences, Lithuania)*; 
Annamari Lundqvist (National Institute for Health and Welfare, 
Finland)*; Per Lytsy (University of Uppsala, Sweden)*; Guansheng Ma 
(Peking University, China)*; George L L Machado-Coelho (Universidade 
Federal de Ouro Preto, Brazil)*; Suka Machi (The Jikei University School 
of Medicine, Japan)*; Stefania Maggi (National Research Council, Italy)*; 
Dianna J Magliano (Baker IDI Heart and Diabetes Institute, Australia)*; 
Marcia Makdisse (Hospital Israelita Albert Einstein, Brazil)*; 
Kodavanti Mallikharjuna Rao (Indian Council of Medical Research, 
India)*; Yannis Manios (Harokopio University, Greece)*; Enzo Manzato 
(University of Padova, Italy)*; Paula Margozzini (Pontiﬁ cia Universidad 
Católica de Chile, Chile)*; Pedro Marques-Vidal (Lausanne University 
Hospital, Switzerland)*; Reynaldo Martorell (Emory University, USA)*; 
Shariq R Masoodi (Sher-i-Kashmir Institute of Medical Sciences, India)*; 
Ellisiv B Mathiesen (UiT The Arctic University of Norway, Norway)*; 
Tandi E Matsha (Cape Peninsula University of Technology, South 
Africa)*; Jean Claude N Mbanya (University of Yaoundé 1, Cameroon)*; 
Shelly R McFarlane (The University of the West Indies, Jamaica)*; 
Stephen T McGarvey (Brown University, USA)*; Stela McLachlan 
(University of Edinburgh, UK)*; Breige A McNulty (University College 
Dublin, Ireland)*; Sounnia Mediene-Benchekor (University of Oran 1, 
Algeria)*; Aline Meirhaeghe (INSERM, France)*; Ana Maria B Menezes 
(Universidade Federal de Pelotas, Brazil)*; Shahin Merat (Digestive 
Disease Research Institute, Iran)*; Indrapal I Meshram (Indian Council 
of Medical Research, India)*; Jie Mi (Capital Institute of Pediatrics, 
China)*; Juan Francisco Miquel (Pontiﬁ cia Universidad Católica de 
Chile, Chile)*; J Jaime Miranda (Universidad Peruana Cayetano Heredia, 
Peru)*; Mostafa K Mohamed (Ain Shams University, Egypt)*; 
Kazem Mohammad (Tehran University of Medical Sciences, Iran)*; 
Noushin Mohammadifard (Isfahan Cardiovascular Research Center, 
Iran)*; Viswanathan Mohan (Madras Diabetes Research Foundation, 
India)*; Muhammad Fadhli Mohd Yusoﬀ  (Ministry of Health Malaysia, 
Malaysia)*; Niels C Møller (University of Southern Denmark, 
Denmark)*; Dénes Molnár (University of Pécs, Hungary)*; 
Charles K Mondo (Mulago Hospital, Uganda)*; Alain Morejon 
(University Medical Science, Cuba)*; Luis A Moreno (Universidad de 
Zaragoza, Spain)*; Karen Morgan (RCSI Dublin, Ireland)*; 
George Moschonis (Harokopio University, Greece)*; 
Malgorzata Mossakowska (International Institute of Molecular and Cell 
Biology, Poland)*; Aya Mostafa (Ain Shams University, Egypt)*; 
Jorge Mota (University of Porto, Portugal)*; Jorge Motta (Gorgas 
Memorial Institute of Public Health, Panama)*; Thet Thet Mu 
(Department of Public Health, Myanmar)*; Maria Lorenza Muiesan 
(University of Brescia, Italy)*; Martina Müller-Nurasyid (Helmholtz 
Zentrum München, Germany)*; Jaakko Mursu (University of Eastern 
Finland, Finland)*; Gabriele Nagel (Ulm University, Germany)*; 
Jana Námešná (Regional Authority of Public Health, Banska Bystrica, 
Slovakia)*; Ei Ei K Nang (National University of Singapore, Singapore)*; 
Vinay B Nangia (Suraj Eye Institute, India)*; Eva Maria Navarrete-Muñoz 
(CIBER en Epidemiología y Salud Pública, Spain)*; 
Ndeye Coumba Ndiaye (INSERM, France)*; Ilona Nenko (Jagiellonian 
University Medical College, Poland)*; Flavio Nervi (Pontiﬁ cia 
Universidad Católica de Chile, Chile)*; Nguyen D Nguyen (University of 
Pharmacy and Medicine of Ho Chi Minh City, Vietnam)*; 
Quang Ngoc Nguyen (Hanoi Medical University, Vietnam)*; 
Ramﬁ s E Nieto-Martínez (Universidad Centro-Occidental Lisandro 
Alvarado, Venezuela)*; Guang Ning (Shanghai Jiao-Tong University 
School of Medicine, China)*; Toshiharu Ninomiya (Kyushu University, 
Japan)*; Marianna Noale (National Research Council, Italy)*; 
Davide Noto (University of Palermo, Italy)*; Mohannad Al Nsour 
(Eastern Mediterranean Public Health Network, Jordan)*; 
Angélica M Ochoa-Avilés (Universidad de Cuenca, Ecuador)*; 
Kyungwon Oh (Korea Centers for Disease Control and Prevention, 
Republic of Korea)*; Altan Onat (Istanbul University, Turkey)*; 
Pedro Ordunez (Pan American Health Organization, USA)*; 
Clive Osmond (MRC Lifecourse Epidemiology Unit, UK)*; 
Johanna A Otero (Fundación Oftalmológica de Santander, Colombia)*; 
Ellis Owusu-Dabo (Kwame Nkrumah University of Science and 
Technology, Ghana)*; Elena Pahomova (University of Latvia, Latvia)*; 
Luigi Palmieri (Istituto Superiore di Sanità, Italy)*; 
Songhomitra Panda-Jonas (Ruprecht-Karls-University of Heidelberg, 
Germany)*; Francesco Panza (University of Bari, Italy)*; 
Mahboubeh Parsaeian (Non-Communicable Diseases Research Center, 
Iran)*; Sergio Viana Peixoto (Oswaldo Cruz Foundation Rene Rachou 
Research Institute, Brazil)*; Catherine Pelletier (Public Health Agency of 
Canada, Canada)*; Markku Peltonen (National Institute for Health and 
Welfare, Finland)*; Annette Peters (Helmholtz Zentrum München, 
Germany)*; Niloofar Peykari (Non-Communicable Diseases Research 
Center, Iran)*; Son Thai Pham (Vietnam National Heart Institute, 
Vietnam)*; Aida Pilav (Federal Ministry of Health, Bosnia and 
Herzegovina)*; Freda Pitakaka (University of New South Wales, 
Australia)*; Aleksandra Piwonska (The Cardinal Wyszynski Institute of 
Cardiology, Poland)*; Jerzy Piwonski (The Cardinal Wyszynski Institute 
of Cardiology, Poland)*; Pedro Plans-Rubió (Public Health Agency of 
Catalonia, Spain)*; Miquel Porta (Institut Hospital del Mar 
d’Investigacions Mèdiques, Spain)*; Marileen L P Portegies (Erasmus 
Medical Center Rotterdam, Netherlands)*; Hossein Poustchi (Tehran 
University of Medical Sciences, Iran)*; Rajendra Pradeepa (Madras 
Diabetes Research Foundation, India)*; Jacqueline F Price (University of 
Edinburgh, UK)*; Margus Punab (Tartu University Clinics, Estonia)*; 
Radwan F Qasrawi (Al-Quds University, Palestine)*; Mostafa Qorbani 
(Alborz University of Medical Sciences, Iran)*; Ricardas Radisauskas 
(Lithuanian University of Health Sciences, Lithuania)*; 
Mahmudur Rahman (Institute of Epidemiology Disease Control and 
Research, Bangladesh)*; Olli Raitakari (University of Turku, Finland)*; 
Sudha Ramachandra Rao (National Institute of Epidemiology, India)*; 
Ambady Ramachandran (India Diabetes Research Foundation, India)*; 
Jacqueline Ramke (University of New South Wales, Australia)*; 
Rafel Ramos (Institut Universitari d’Investigació en Atenció Primària 
Jordi Gol, Spain)*; Sanjay Rampal (University of Malaya, Malaysia)*; 
Wolfgang Rathmann (German Diabetes Center, Germany)*; Josep Redon 
(University of Valencia, Spain)*; Paul Ferdinand M Reganit (University 
of the Philippines, Philippines)*; Fernando Rigo (Health Center San 
Agustín, Spain)*; Sian M Robinson (University of Southampton, UK)*; 
Cynthia Robitaille (Public Health Agency of Canada, Canada)*; 
Fernando Rodríguez-Artalejo (Universidad Autónoma de Madrid, 
Spain)*; María del Cristo Rodriguez-Perez (Canarian Health Service, 
Spain)*; Laura A Rodríguez-Villamizar (Universidad Industrial de 
Santander, Colombia)*; Rosalba Rojas-Martinez (Instituto Nacional de 
Salud Pública, Mexico)*; Kimmo Ronkainen (University of Eastern 
Finland, Finland)*; Annika Rosengren (University of Gothenburg, 
Sweden)*; Adolfo Rubinstein (Institute for Clinical Eﬀ ectiveness and 
Health Policy, Argentina)*; Ornelas Rui (University of Madeira, 
Portugal)*; Blanca Sandra Ruiz-Betancourt (Instituto Mexicano del 
Seguro Social, Mexico)*; Andrea RV Russo Horimoto (Heart Institute, 
Brazil)*; Marcin Rutkowski (Medical University of Gdansk, Poland)*; 
Charumathi Sabanayagam (Singapore Eye Research Institute, 
Articles
1528 www.thelancet.com   Vol 387   April 9, 2016
Singapore)*; Harshpal S Sachdev (Sitaram Bhartia Institute of Science 
and Research, India)*; Olfa Saidi (University Tunis El Manar, Tunisia)*; 
Sibel Sakarya (Marmara University, Turkey)*; Benoit Salanave (French 
Institute for Health Surveillance, France)*; Jukka T Salonen (University 
of Helsinki, Finland)*; Massimo Salvetti (University of Brescia, Italy)*; 
Jose Sánchez-Abanto (National Institute of Health, Peru)*; Diana Santos 
(University of Lisbon, Portugal)*; Renata Nunes dos Santos (University 
of São Paulo Clinics Hospital, Brazil)*; Rute Santos (University of Porto, 
Portugal)*; Jouko L Saramies (South Karelia Social and Health Care 
District, Finland)*; Luis B Sardinha (University of Lisbon, Portugal)*; 
Nizal Sarrafzadegan (Isfahan Cardiovascular Research Center, Iran)*; 
Kai-Uwe Saum (German Cancer Research Center, Germany)*; 
Marcia Scazufca (University of São Paulo Clinics Hospital, Brazil)*; 
Herman Schargrodsky (Hospital Italiano de Buenos Aires, Argentina)*; 
Christa Scheidt-Nave (Robert Koch Institute, Germany)*; Aye Aye Sein 
(Ministry of Health, Myanmar)*; Sanjb K Sharma (B P Koirala Institute 
of Health Sciences, Nepal)*; Jonathan E Shaw (Baker IDI Heart and 
Diabetes Institute, Australia)*; Kenji Shibuya (The University of Tokyo, 
Japan)*; Youchan Shin (Singapore Eye Research Institute, Singapore)*; 
Rahman Shiri (Finnish Institute of Occupational Health, Finland)*; 
Rosalynn Siantar (Singapore Eye Research Institute, Singapore)*; 
Abla M Sibai (American University of Beirut, Lebanon)*; Mary Simon 
(India Diabetes Research Foundation, India)*; Judith Simons 
(St Vincent’s Hospital, Australia)*; Leon A Simons (University of New 
South Wales, Australia)*; Michael Sjostrom (Karolinska Institutet, 
Sweden)*; Jolanta Slowikowska-Hilczer (Medical University of Łodz, 
Poland)*; Przemyslaw Slusarczyk (International Institute of Molecular 
and Cell Biology, Poland)*; Liam Smeeth (London School of Hygiene & 
Tropical Medicine, UK)*; Marieke B Snijder (Academic Medical Center 
of University of Amsterdam, Netherlands)*; Hung-Kwan So (The 
Chinese University of Hong Kong, China)*; Eugène Sobngwi (University 
of Yaoundé 1, Cameroon)*; Stefan Söderberg (Umeå University, 
Sweden)*; Vincenzo Solfrizzi (University of Bari, Italy)*; 
Emily Sonestedt (Lund University, Sweden)*; Aicha Soumare (University 
of Bordeaux, France)*; Jan A Staessen (University of Leuven, Belgium)*; 
Maria G Stathopoulou (INSERM, France)*; Jostein Steene-Johannessen 
(Norwegian School of Sport Sciences, Norway)*; Peter Stehle (Bonn 
University, Germany)*; Aryeh D Stein (Emory University, USA)*; 
Jochanan Stessman (Hadassah University Medical Center, Israel)*; 
Doris Stöckl (Helmholtz Zentrum München, Germany)*; 
Jakub Stokwiszewski (National Institute of Hygiene, Poland)*; 
Karien Stronks (University of Amsterdam, Netherlands)*; 
Maria Wany Strufaldi (Federal University of São Paulo, Brazil)*; 
Chien-An Sun (Fu Jen Catholic University, Taiwan)*; Johan Sundström 
(Uppsala University, Sweden)*; Yn-Tz Sung (The Chinese University of 
Hong Kong, China)*; Paibul Suriyawongpaisal (Mahidol University, 
Thailand)*; Rody G Sy (University of the Philippines, Philippines)*; 
E Shyong Tai (National University of Singapore, Singapore)*; 
Abdonas Tamosiunas (Lithuanian University of Health Sciences, 
Lithuania)*; Line Tang (Research Centre for Prevention and Health, 
Denmark)*; Mohammed Tarawneh (Ministry of Health, Jordan)*; 
Carolina B Tarqui-Mamani (National Institute of Health, Peru)*; 
Anne Taylor (The University of Adelaide, Australia)*; Holger Theobald 
(Karolinska Institutet, Sweden)*; Lutgarde Thijs (University of Leuven, 
Belgium)*; Betina H Thuesen (Research Centre for Prevention and 
Health, Denmark)*; Hanna K Tolonen (National Institute for Health and 
Welfare, Finland)*; Janne S Tolstrup (University of Southern Denmark, 
Denmark)*; Murat Topbas (Karadeniz Technical University, Turkey)*; 
Maties Torrent (IB-SALUT Area de Salut de Menorca, Spain)*; 
Pierre Traissac (Institut de Recherche pour le Développement, France)*; 
Oanh T H Trinh (University of Pharmacy and Medicine of Ho Chi Minh 
City, Vietnam)*; Marshall K Tulloch-Reid (The University of the West 
Indies, Jamaica)*; Tomi-Pekka Tuomainen (University of Eastern 
Finland, Finland)*; Maria L Turley (Ministry of Health, New Zealand)*; 
Christophe Tzourio (University of Bordeaux, France)*; Peter Ueda 
(Harvard T H Chan School of Public Health, USA)*; Flora A M Ukoli 
(Meharry Medical College, USA)*; Hanno Ulmer (Medical University of 
Innsbruck, Austria)*; Hannu M T Uusitalo (Tampere University 
Hospital, Finland)*; Gonzalo Valdivia (Pontiﬁ cia Universidad Católica de 
Chile, Chile)*; Damaskini Valvi (Harvard T H Chan School of Public 
Health, USA)*; Lenie van Rossem (University Medical Center Utrecht, 
Netherlands)*; Irene GM van Valkengoed (Academic Medical Center of 
University of Amsterdam, Netherlands)*; Dirk Vanderschueren 
(Katholieke Universiteit Leuven, Belgium)*; Diego Vanuzzo (Centro di 
Prevenzione Cardiovascolare Udine, Italy)*; Tomas Vega (Consejería de 
Sanidad Junta de Castilla y León, Spain)*; Gustavo Velasquez-Melendez 
(Universidade Federal de Minas Gerais, Brazil)*; Giovanni Veronesi 
(University of Insubria, Italy)*; W M Monique Verschuren (National 
Institute for Public Health and the Environment, Netherlands)*; 
Roosmarijn Verstraeten (Institute of Tropical Medicine, Belgium)*; 
Lucie Viet (National Institute for Public Health and the Environment, 
Netherlands)*; Jesus Vioque (Universidad Miguel Hernandez, Spain)*; 
Jyrki K Virtanen (University of Eastern Finland, Finland)*; 
Sophie Visvikis-Siest (INSERM, France)*; Bharathi Viswanathan 
(Ministry of Health, Seychelles)*; Peter Vollenweider (Lausanne 
University Hospital, Switzerland)*; Sari Voutilainen (University of 
Eastern Finland, Finland)*; Martine Vrijheid (Centre for Research in 
Environmental Epidemiology, Spain)*; Alisha N Wade (University of the 
Witwatersrand, South Africa)*; Aline Wagner (University of Strasbourg, 
France)*; Janette Walton (University College Cork, Ireland)*; 
Wan Nazaimoon Wan Mohamud (Institute for Medical Research, 
Malaysia)*; Feng Wang (Peking University Sixth Hospital, China)*; 
Ming-Dong Wang (Public Health Agency of Canada, Canada)*; 
Qian Wang (Xinjiang Medical University, China)*; Ya Xing Wang 
(Beijing Tongren Hospital, China)*; S Goya Wannamethee (University 
College London, UK)*; Deepa Weerasekera (Ministry of Health, New 
Zealand)*; Peter H Whincup (St George’s, University of London, UK)*; 
Kurt Widhalm (Medical University of Vienna, Austria)*; Andrzej Wiecek 
(Medical University of Silesia, Poland)*; Alet H Wijga (National Institute 
for Public Health and the Environment, Netherlands)*; Rainford J Wilks 
(The University of the West Indies, Jamaica)*; Johann Willeit (Medical 
University Innsbruck, Austria)*; Tom Wilsgaard (UiT The Arctic 
University of Norway, Norway)*; Bogdan Wojtyniak (National Institute of 
Hygiene, Poland)*; Tien Yin Wong (Duke-NUS Graduate Medical 
School, Singapore)*; Jean Woo (The Chinese University of Hong Kong, 
China)*; Mark Woodward (University of Sydney, Australia; University of 
Oxford, UK)*; Frederick C Wu (University of Manchester, UK)*; 
Shou Ling Wu (Kailuan General Hospital, China)*; Haiquan Xu 
(Institute of Food and Nutrition Development of Ministry of Agriculture, 
China)*; Weili Yan (Fudan University, China)*; Xiaoguang Yang 
(Chinese Center for Disease Control and Prevention, China)*; 
Xingwang Ye (University of Chinese Academy of Sciences, China)*; 
Akihiro Yoshihara (Niigata University, Japan)*; 
Novie O Younger-Coleman (The University of the West Indies, 
Jamaica)*; Sabina Zambon (University of Padova, Italy)*; 
Abdul Hamid Zargar (Center for Diabetes and Endocrine Care, India)*; 
Tomasz Zdrojewski (Medical University of Gdansk, Poland)*; 
Wenhua Zhao (Chinese Center for Disease Control and Prevention, 
China)*; Yingfeng Zheng (Singapore Eye Research Institute, 
Singapore)*; Julio Zuñiga Cisneros (Gorgas Memorial Institute of Public 
Health, Panama)*.
Declaration of interests
ME reports a charitable grant from Youth Health Programme of 
AstraZeneca, outside the submitted work. JAR reports personal fees 
from Tres Montes Lucchetti and grants from Danone Mexico, outside 
the submitted work. All other members of the Pooled Analysis and 
Writing Group declare no competing interests.
Acknowledgments
The study was funded by the Wellcome Trust. We thank Christina Banks, 
Dheeya Rizmie, and Yasaman Vali for assistance with data extraction. 
We thank WHO country and regional oﬃ  ces and the World Heart 
Federation for support in data identiﬁ cation and access.
References
 1 Global Burden of Metabolic Risk Factors for Chronic Diseases 
Collaboration. Cardiovascular disease, chronic kidney disease, and 
diabetes mortality burden of cardiometabolic risk factors from 1980 
to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 
2014; 2: 634–47.
 2 Seuring T, Archangelidi O, Suhrcke M. The economic costs of 
type 2 diabetes: a global systematic review. Pharmacoeconomics 2015; 
33: 811–31.
Articles
www.thelancet.com   Vol 387   April 9, 2016 1529
 3 WHO. Global action plan for the prevention and control of 
noncommunicable diseases 2013–2020. 2013. http://apps.who.int/
iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1 
(accessed Aug 14, 2015).
 4 Danaei G, Finucane MM, Lu Y, et al. National, regional, and global 
trends in fasting plasma glucose and diabetes prevalence since 
1980: systematic analysis of health examination surveys and 
epidemiological studies with 370 country-years and 2·7 million 
participants. Lancet 2011; 378: 31–40.
 5 Guariguata L, Whiting DR, Hambleton I, Beagley J, 
Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence 
for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 
103: 137–49.
 6 International Diabetes Federation. IDF Diabetes Atlas, 6th edn. 
Brussels: International Diabetes Federation, 2013.
 7 Guariguata L, Whiting D, Weil C, Unwin N. The International 
Diabetes Federation Diabetes Atlas methodology for estimating 
global and national prevalence of diabetes in adults. 
Diabetes Res Clin Pract 2011; 94: 322–32.
 8 NCD Risk Factor Collaboration. Eﬀ ects of diabetes deﬁ nition on 
global surveillance of diabetes prevalence and diagnosis: a pooled 
analysis of 96 population-based studies with 331 288 participants. 
Lancet Diabetes Endocrinol 2015; 3: 624–37.
 9 Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of 
undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014; 
103: 150–60.
 10 Zhang X, Geiss LS, Cheng YJ, Beckles GL, Gregg EW, Kahn HS. 
The missed patient with diabetes: how access to health care aﬀ ects 
the detection of diabetes. Diabetes Care 2008; 31: 1748–53.
 11 Gakidou E, Mallinger L, Abbott-Klafter J, et al. Management of 
diabetes and associated cardiovascular risk factors in seven 
countries: a comparison of data from national health examination 
surveys. Bull World Health Organ 2011; 89: 172–83.
 12 Finucane MM, Paciorek CJ, Danaei G, Ezzati M. Bayesian 
estimation of population-level trends in measures of health status. 
Stat Sci 2014; 29: 18–25.
 13 Danaei G, Finucane MM, Lin JK, et al. National, regional, and 
global trends in systolic blood pressure since 1980: systematic 
analysis of health examination surveys and epidemiological studies 
with 786 country-years and 5·4 million participants. Lancet 2011; 
377: 568–77.
 14 Stevens GA, Bennett JE, Hennocq Q, et al. Trends and mortality 
eﬀ ects of vitamin A deﬁ ciency in children in 138 low-income and 
middle-income countries between 1991 and 2013: a pooled 
analysis of population-based surveys. Lancet Glob Health 2015; 
3: e528–36.
 15 Singh GM, Danaei G, Pelizzari PM, et al. The age associations of 
blood pressure, cholesterol, and glucose: analysis of health 
examination surveys from international populations. Circulation 
2012; 125: 2204–11.
 16 NCD Risk Factor Collaboration (NCD-RisC). Trends in adult 
body-mass index in 200 countries from 1975 to 2014: a pooled 
analysis of 1698 population-based measurement studies with 
19·2 million participants. Lancet 2016; 387: 1377–96.
 17 Ezzati M, Riboli E. Behavioral and dietary risk factors for 
noncommunicable diseases. N Engl J Med 2013; 369: 954–64.
 18 Wandell PE, Carlsson AC. Gender diﬀ erences and time trends in 
incidence and prevalence of type 2 diabetes in Sweden--a model 
explaining the diabetes epidemic worldwide today? 
Diabetes Res Clin Pract 2014; 106: e90–92.
 19 Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001; 
44: 3–15.
 20 Hwang CK, Han PV, Zabetian A, Ali MK, Narayan KM. Rural 
diabetes prevalence quintuples over twenty-ﬁ ve years in low- and 
middle-income countries: a systematic review and meta-analysis. 
Diabetes Res Clin Pract 2012; 96: 271–85.
 21 A mass survey of diabetes mellitus in a population of 300,000 in 
14 provinces and municipalities in China (author’s transl). 
Zhonghua Nei Ke Za Zhi 1981; 20: 678–83 (in Chinese).
 22 Eliasson M, Lindahl B, Lundberg V, Stegmayr B. No increase in the 
prevalence of known diabetes between 1986 and 1999 in subjects 
25–64 years of age in northern Sweden. Diabet Med 2002; 
19: 874–80.
 23 Icks A, Moebus S, Feuersenger A, Haastert B, Jockel KH, Giani G. 
Diabetes prevalence and association with social status--widening of 
a social gradient? German national health surveys 1990–1992 and 
1998. Diabetes Res Clin Pract 2007; 78: 293–97.
 24 Teuscher AU, Diem P, Thomas W, Janett J, Teuscher A. Incidence 
of insulin-dependent diabetes mellitus in Switzerland (1972–1993) 
in 19-year-old men. Schweiz Med Wochenschr 1995; 125: 1041–45 
(in German).
 25 Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and 
trends in diabetes among adults in the United States, 1988–2012. 
JAMA 2015; 314: 1021–29.
 26 Imkampe AK, Gulliford MC. Increasing socio-economic inequality 
in type 2 diabetes prevalence--repeated cross-sectional surveys in 
England 1994–2006. Eur J Public Health 2011; 21: 484–90.
 27 Hamer M, Kengne AP, Batty GD, Cooke D, Stamatakis E. Temporal 
trends in diabetes prevalence and key diabetes risk factors in 
Scotland, 2003–2008. Diabet Med 2011; 28: 595–98.
 28 Charvat H, Goto A, Goto M, et al. Impact of population aging on 
trends in diabetes prevalence: A meta-regression analysis of 
160,000 Japanese adults. J Diabetes Investig 2015; 6: 533–42.
 29 Li MZ, Su L, Liang BY, et al. Trends in prevalence, awareness, 
treatment, and control of diabetes mellitus in mainland China from 
1979 to 2012. Int J Endocrinol 2013; 2013: 753150.
 30 Zuo H, Shi Z, Hussain A. Prevalence, trends and risk factors for the 
diabetes epidemic in China: a systematic review and meta-analysis. 
Diabetes Res Clin Pract 2014; 104: 63–72.
 31 Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, 
Hills AP. Prevalence and trends of the diabetes epidemic in South 
Asia: a systematic review and meta-analysis. BMC Public Health 
2012; 12: 380.
 32 Misra P, Upadhyay RP, Misra A, Anand K. A review of the 
epidemiology of diabetes in rural India. Diabetes Res Clin Pract 2011; 
92: 303–11.
 33 Mohan V, Deepa M, Deepa R, et al. Secular trends in the prevalence 
of diabetes and impaired glucose tolerance in urban 
South India—the Chennai Urban Rural Epidemiology Study 
(CURES-17). Diabetologia 2006; 49: 1175–78.
 34 Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in 
prevalence of diabetes in Asian countries. World J Diabetes 2012; 
3: 110–17.
 35 Esteghamati A, Etemad K, Koohpayehzadeh J, et al. Trends in the 
prevalence of diabetes and impaired fasting glucose in association 
with obesity in Iran: 2005–2011. Diabetes Res Clin Pract 2014; 
103: 319–27.
 36 Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the 
prevalence and risk factors of diabetes and prediabetes in Turkish 
adults. Eur J Epidemiol 2013; 28: 169–80.
 37 Alharbi NS, Almutari R, Jones S, Al-Daghri N, Khunti K, 
de Lusignan S. Trends in the prevalence of type 2 diabetes mellitus 
and obesity in the Arabian Gulf States: systematic review and 
meta-analysis. Diabetes Res Clin Pract 2014; 106: e30–33.
 38 Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes 
mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 
35: 595–601.
 39 Chambers JC, Zhang W, Zabaneh D, et al. Common genetic 
variation near melatonin receptor MTNR1B contributes to raised 
plasma glucose and increased risk of type 2 diabetes among 
Indian Asians and European Caucasians. Diabetes 2009; 
58: 2703–08.
 40 Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. 
Lancet 2010; 375: 408–18.
 41 Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes 
in childhood body-mass index to impaired glucose tolerance in 
young adulthood. N Engl J Med 2004; 350: 865–75.
 42 Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk 
factors, and pathophysiology. JAMA 2009; 301: 2129–40.
 43 Colagiuri R, Colagiuri S, Yach D, Pramming S. The answer to 
diabetes prevention: science, surgery, service delivery, or social 
policy? Am J Public Health 2006; 96: 1562–69.
 44 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the 
incidence of type 2 diabetes with lifestyle intervention or 
metformin. N Engl J Med 2002; 346: 393–403.
Articles
1530 www.thelancet.com   Vol 387   April 9, 2016
 45 Farzadfar F, Murray CJ, Gakidou E, et al. Eﬀ ectiveness of diabetes 
and hypertension management by rural primary health-care 
workers (Behvarz workers) in Iran: a nationally representative 
observational study. Lancet 2012; 379: 47–54.
 46 Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management 
of type 2 diabetes: dietary components and nutritional strategies. 
Lancet 2014; 383: 1999–2007.
 47 Sutheran HL, Reynolds T. Technical and clinical accuracy of three 
blood glucose meters: clinical impact assessment using error grid 
analysis and insulin sliding scales. J Clin Pathol 2016; published 
online Feb 5. DOI: 10.1136/jclinpath-2015-203339.
 48 Pfutzner A, Mitri M, Musholt PB, et al. Clinical assessment of the 
accuracy of blood glucose measurement devices. Curr Med Res Opin 
2012; 28: 525–31.
 49 Diaz-Valencia PA, Bougneres P, Valleron AJ. Global epidemiology 
of type 1 diabetes in young adults and adults: a systematic review. 
BMC Public Health 2015; 15: 255.
 50 Tuomilehto J. The emerging global epidemic of type 1 diabetes. 
Curr Diab Rep 2013; 13: 795–804.
 51 American Diabetes Association. Diagnosis and classiﬁ cation of 
diabetes mellitus. Diabetes Care 2004; 27 (suppl 1): S5–10.
 52 Centers for Disease Control and Prevention. National diabetes 
statistics report: estimates of diabetes and its burden in the United 
States, 2014. Atlanta, GA: US Department of Health and Human 
Services, 2014.
 53 Global Burden of Disease Study Collaborators. Global, regional, and 
national incidence, prevalence, and years lived with disability for 
301 acute and chronic diseases and injuries in 188 countries, 
1990–2013: a systematic analysis for the Global Burden of Disease 
Study 2013. Lancet 2015; 386: 743–800.
 54 Pan SC, Ku CC, Kao D, Ezzati M, Fang CT, Lin HH. Eﬀ ect of 
diabetes on tuberculosis control in 13 countries with high 
tuberculosis: a modelling study. Lancet Diabetes Endocrinol 2015; 
3: 323–30.
 55 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 
10-year follow-up of intensive glucose control in type 2 diabetes. 
N Engl J Med 2008; 359: 1577–89.
 56 The ADVANCE Collaborative Group. Intensive blood glucose 
control and vascular outcomes in patients with type 2 diabetes. 
N Engl J Med 2008; 358: 2560–72.
 57 The Look AHEAD Research Group. Eﬀ ect of a long-term 
behavioural weight loss intervention on nephropathy in overweight 
or obese adults with type 2 diabetes: a secondary analysis of the 
Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 
2014; 2: 801–09.
 58 Holman RR, Sourij H, Caliﬀ  RM. Cardiovascular outcome trials of 
glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 
383: 2008–17.
 59 Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control 
and the prevention of cardiovascular events: implications of the 
ACCORD, ADVANCE, and VA diabetes trials: a position statement 
of the American Diabetes Association and a scientiﬁ c statement of 
the American College of Cardiology Foundation and the American 
Heart Association. Circulation 2009; 119: 351–57.
 60 Cefalu WT. Glycemic targets and cardiovascular disease. 
N Engl J Med 2008; 358: 2633–35.
 61 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. 
Multifactorial intervention and cardiovascular disease in patients 
with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
 62 Fox CS, Golden SH, Anderson C, et al. Update on prevention of 
cardiovascular disease in adults with type 2 diabetes mellitus in 
light of recent evidence: a scientiﬁ c statement from the American 
Heart Association and the American Diabetes Association. 
Circulation 2015; 132: 691–718.
 63 Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, 
Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. 
N Engl J Med 2013; 368: 1613–24.
 64 Gregg EW, Albright AL. The public health response to diabetes--two 
steps forward, one step back. JAMA 2009; 301: 1596–98.
 65 Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related 
complications in the United States, 1990–2010. N Engl J Med 2014; 
370: 1514–23.
 66 Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 
diabetes mellitus by changes in lifestyle among subjects with 
impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50.
 67 Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes 
Prevention Programme shows that lifestyle modiﬁ cation and 
metformin prevent type 2 diabetes in Asian Indian subjects with 
impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289–97.
 68 Saaristo T, Moilanen L, Korpi-Hyovalti E, et al. Lifestyle intervention 
for prevention of type 2 diabetes in primary health care: one-year 
follow-up of the Finnish National Diabetes Prevention Program 
(FIN-D2D). Diabetes Care 2010; 33: 2146–51.
 69 DePue JD, Dunsiger S, Seiden AD, et al. Nurse-community health 
worker team improves diabetes care in American Samoa: results of 
a randomized controlled trial. Diabetes Care 2013; 36: 1947–53.
 70 Narayan KM, Echouﬀ o-Tcheugui JB, Mohan V, Ali MK. Analysis & 
commentary: global prevention and control of type 2 diabetes will 
require paradigm shifts in policies within and among countries. 
Health Aﬀ  (Millwood) 2012; 31: 84–92.
